Product Description
PLN-74809, is a small-molecule, dual selective inhibitor of alphaVbeta1 / alphaVbeta6 for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). These integrins cause upstream activation of TGF-beta1 in actively fibrotic tissue. Inhibition of these integrins will block TGF-beta1 activation, thereby preventing the growth of fibrotic tissue within the lung and bile ducts. PLN-74809 has entered clinical testing, following FDA- approval of the IND. (Sourced from: https://www.pulmonaryfibrosis.org/patients-caregivers/medical-and-support-resources/clinical-trials-education-center/pipeline/drug/idiopathic-pulmonary-fibrosis/pln-74809)
Mechanisms of Action: aVb1 Inhibitor,aVb6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Cholangitis|Cholangitis, SclerosingFast Track - Idiopathic Pulmonary Fibrosis|Pulmonary FibrosisOrphan Drug - Idiopathic Pulmonary Fibrosis|Pulmonary Fibrosis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pliant
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Bernard Coulie
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Pliant announced they will present P2 Idiopathic Pulmonary Fibrosis results in 2Q25 for Bexotegrast
- Clinical Outcomes Reported - Pliant presented P2 Idiopathic Pulmonary Fibrosis results on 2025-03-03 for Bexotegrast
- Clinical Outcomes Reported - Pliant presented P2 Idiopathic Pulmonary Fibrosis results on 2025-02-07 for Bexotegrast
Highest Development Phases
Phase 3: Idiopathic Pulmonary Fibrosis
Phase 2: Cholangitis, Sclerosing
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BEACON-IPF | P2 |
Active, not recruiting |
Idiopathic Pulmonary Fibrosis |
2025-08-31 |
12% |
2025-02-21 |
Primary Endpoints|Treatments|Trial Status |
| INTEGRIS-PSC | P2 |
Completed |
Cholangitis, Sclerosing |
2024-02-26 |
55% |
2024-04-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| PLN-74809 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2023-12-27 |
13% |
2024-02-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| INTEGRIS-IPF | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2023-02-01 |
50% |
2023-06-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| jRCT2051240025 | P3 |
Not yet recruiting |
Idiopathic Pulmonary Fibrosis |
2026-09-01 |
|||
| PLN-74809-IPF-206 | P3 |
Completed |
Idiopathic Pulmonary Fibrosis |
2025-03-03 |
2025-05-02 |
Treatments |